Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine (Q45404942)

14 December 2017

Modeling the long-term antibody response of a human papillomavirus (HPV) virus-like particle (VLP) type 16 prophylactic vaccine (English)

1 reference

14 December 2017

1 reference

1 reference

0 references

1

1 reference

14 December 2017

6

Anna R Giuliano

1 reference

14 December 2017

Joanne E Tomassini

2

1 reference

14 December 2017

Liwen Xi

3

1 reference

14 December 2017

Greg Golm

4

1 reference

14 December 2017

Michael Watson

5

1 reference

14 December 2017

Eliav Barr

7

1 reference

14 December 2017

Kevin A Ault

8

1 reference

14 December 2017

language of work or name

English

0 references

publication date

12 March 2007

1 reference

14 December 2017

10

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

14 December 2017

25

1 reference

14 December 2017

21

1 reference

14 December 2017

4324-4333

1 reference

The causal relation between human papillomavirus and cervical cancer

14 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Can screening for cervical cancer be improved, especially in developing countries?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

A controlled trial of a human papillomavirus type 16 vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Efficacy of Human Papillomavirus-16 Vaccine to Prevent Cervical Intraepithelial Neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Modeling the impact of subclinical measles transmission in vaccinated populations with waning immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Long-term immunogenicity of an inactivated virosome hepatitis A vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Measles seroepidemiology and decay rate of vaccine-induced measles IgG titers in Taiwan, 1995-1997.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Modelling antibody response to measles vaccine and subsequent waning of immunity in a low exposure population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Kinetics of the IgG antibody response to pertussis toxin after infection with B. pertussis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

A mathematical model predicting anti-hepatitis B virus surface antigen (HBs) decay after vaccination against hepatitis B.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

B-cell kinetics in humans: rapid turnover of peripheral blood memory cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Maintenance of serum antibody levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Maintenance of serological memory by polyclonal activation of human memory B cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Antibody Dynamics in Childhood Diseases: Waning and Boosting of Immunity and the Impact of Vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Waning immunity and subclinical measles infections in England.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Age-specific long-term course of IgG antibodies to pertussis toxin after symptomatic infection with Bordetella pertussis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Antibody, cytokine and cytotoxic T lymphocyte responses in chimpanzees immunized with human papillomavirus virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Epidemiology of Genital Human Papillomavirus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

On immunity against infections and vaccines: credo 2004.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Immune responses to human papillomavirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Natural history of human papillomavirus type 16 virus-like particle antibodies in young women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

Analysis of the relationship between immunogenicity and immunity for viral subunit vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.02.069

10.1016/J.VACCINE.2007.02.069

7 January 2021

Identifiers

DOI

1 reference

14 December 2017

1 reference